**Sun Pharma to Invest $100 Million in Specialty Products for FY26**
Sun Pharmaceutical Industries Ltd is set to maintain its focus on specialty products in FY26, which played a significant role in the growth of India’s largest drugmaker in the previous fiscal year. During an earnings call on Thursday, Chairman and Managing Director Dilip Shanghvi announced plans to invest an additional $100 million to commercialize its new specialty product pipeline in the United States.
In the fourth quarter ending March, the company reported an 8% year-on-year increase in total revenue from operations, reaching ₹12,958.8 crore. However, this figure fell short of the ₹13,254 crore average revenue forecasted by analysts surveyed by Bloomberg. The company’s EBITDA (earnings before interest, taxes, depreciation, and amortization) rose by 22.4% to ₹3,716 crore, while the adjusted net profit, excluding exceptional items, increased by 4.8% year-on-year to ₹2,889 crore.
Despite these gains, Sun Pharma’s net profit experienced a 19% decline year-on-year, totaling ₹2,154 crore in Q4, primarily due to exceptional items, including an impairment on an investment. This result did not meet Bloomberg’s consensus estimate of ₹2,794 crore. For the full fiscal year, total revenue from operations grew by 8.4% to ₹52,578.4 crore in FY25, with the company anticipating consolidated revenue growth in the mid-to-high single digits for FY26. EBITDA increased by 17.3% in FY25, and adjusted net profit surged by 19%, driven by enhanced market share in India and growth in its global specialty business.
Shanghvi highlighted the promising near-term pipeline in global specialty products, including Leqselvi and Unloxcyt, which are expected to significantly improve patient care. Leqselvi, approved for treating severe alopecia areata, is set to launch in the U.S. following a favorable ruling in a patent lawsuit. The company plans to introduce it in the second quarter of the current fiscal year. Unloxcyt, which treats metastatic cutaneous squamous cell carcinoma, has also received approval, with a launch timeline to be shared after the completion of the Checkpoint Therapeutics acquisition.
Shanghvi emphasized the importance of the upcoming investment, stating, “This investment will enable us to significantly strengthen our specialty business for the future.” The funds will be allocated to the commercialization and promotion of new specialty products to healthcare practitioners.
**FAQ**
**What is Sun Pharma’s investment plan for FY26?**
Sun Pharma plans to invest an additional $100 million in FY26 to commercialize its new specialty product pipeline in the U.S., focusing on enhancing its specialty business.
